drugset / Trial / NCT00108758

Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia

NCT00108758

Phase 2 Completed 23 enrolled Novo Nordisk A/S
RandomizedParallel-groupDouble-blindTreatment

Summary

This trial is conducted in Africa, Asia, Europe, South America, and the United States of America (USA). The purpose of this study is to evaluate the effectiveness of secondary prophylactic treatment with NovoSeven® in haemophilia A and B patients with inhibitors.

Timeline

Start
2004-03
Primary completion
2005-11
Completion
2005-11

Drugs

EvaluationDrugModalityDoseRoute
Subject eptacog alfa (activated) Protein / enzyme biologic 90 ug/kg
Subject eptacog alfa (activated) Protein / enzyme biologic 270 ug/kg